Pfizer has announced that the US Food and Drug Administration (FDA) has granted Priority Review for its Biologics License Application (BLA) for elranatamab, an investigational B-cell maturation ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Hundreds of people with a rare and incurable type of blood cancer are set to benefit from a new drug that has been recommended for use on the NHS. Elranatamab, known as Elrexfio and made by Pfizer ...

"This is brilliant news. Elranatamab is part of a brand-new class of drugs in the UK and will have a huge impact on patients and their families," said Myeloma UK's senior policy officer ...